EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Potential repurposing of lapatinib and pazopanib as neuroprotective agents in a rat model of Huntington’s disease

Nada Ezeldine-Elmahalawy, Noha F Abdelkader, Hala F Zaki, Amany I Elbrairy, Sameh S Gad

Inflammopharmacology · 2025

DOI: 10.1007/s10787-025-01933-5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Inflammopharmacology, 2025. Verfasst von Nada Ezeldine-Elmahalawy und 4 weiteren Autor:innen. Beteiligte Einrichtung: Postgraduate program in Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Cairo, Egypt. nada.ezeldine@gmail.com. Hauptthemen laut MEDLINE: Huntington Disease, Pyrimidines, Neuroprotective Agents, Sulfonamides. Die Arbeit nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cairo University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The neuroprotective potential of tyrosine kinase inhibitors (TKIs), potent anticancer drugs, was verified against various neurodegenerative insults, but not Huntington’s disease (HD). These promising outcomes were due to their ability to modulate various intracellular signalling pathways. Hence, the current study aimed to evaluate the neuroprotective effects of lapatinib and pazopanib in the 3-nitropropionic (3-NP)-induced HD model in rats. After 14 days of 3-NP administration, rats received saline, lapatinib, or pazopanib for 21 days. Treatment with lapatinib or pazopanib improved the striatal microscopic architecture, neuronal survival, and neuroinflammatory responses, with a pronounced effect observed for pazopanib. At the molecular level, lapatinib and pazopanib reduced the striatal gene expression of NF-κB and TNF-α receptors, curbed the glutamate/calpain-2 axis, and modified the striatal content of inflammatory molecules as well as neurotransmitters. In addition, they activated the neuroprotective trajectory viz . , m-Tor/ULK-1/Beclin-1/LC3-II, an effect dependent on tyrosine kinase inhibition. Moreover, treated groups showed normalised tyrosine hydroxylase and glial fibrillary acidic protein in the striatum. In conclusion, this study provides strong evidence that lapatinib or pazopanib significantly improved motor function, alleviated cognitive decline, and attenuated neurodegeneration in HD rats via modulating key signalling pathways implicated in HD pathogenesis. These results underscore the promising therapeutic potential of TKIs in managing HD and warrant further investigation into their clinical application. Graphical abstract Schematic representation summarising the mechanisms underlying the neuroprotective effects of Lapatinib and Pazopanib in 3-NP induced Huntington disease in rats. LAP Lapatinib, PAZO pazopanib, ACh acetylcholine, NE norepinephrine, DA dopamine, 5-HT 5-hydroxytryptophan, Glu glutamate, LC3 microtubule-associated protein 1A/1B-light chain, ULK-1 Unc-51 like autophagy activating kinase, m-Tor mammalian target of rapamycin, AKT protein kinase B, PI3K phosphoinositide 3-kinase, TNF-α tumour necrosis alpha, NFκB nuclear factor kappa B, GFAP glial fibrillary acidic protein, TH tyrosine hydroxylase.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Huntington DiseasePyrimidinesNeuroprotective AgentsSulfonamidesLapatinibAnimalsIndazolesRatsDisease Models, AnimalMaleDrug RepositioningCorpus StriatumRats, WistarNitro CompoundsPropionates

Stichwörter der Autor:innen

Glutamate/calpain-2Huntington’s diseaseLapatinib/pazopanibNF-κB/TNF-αPI3K/AKT/m-Tor/Beclin-1/LC3-II/ULK-1Tyrosine kinase inhibitors

Substanzen

pazopanibIndazolesPyrimidinesNeuroprotective AgentsSulfonamidesLapatinib3-nitropropionic acidNitro CompoundsPropionates

Autor:innen und Institutionen

  • Postgraduate program in Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Cairo, Egypt. nada.ezeldine@gmail.com.
  • Department of Pharmacology and Toxicology, Faculty of Pharmacy, October University for Modern Sciences and Arts (MSA University), Giza, Egypt. nada.ezeldine@gmail.com.
  • Department of Pharmacology, Faculty of Pharmacy, Cairo University, Cairo, Egypt. noha.fawzy@pharma.cu.edu.eg.
  • Department of Pharmacology, Faculty of Pharmacy, Cairo University, Cairo, Egypt.
  • Department of Medical Pharmacology, Faculty of Medicine, Cairo University, Giza, Egypt.
  • Department of Medical Pharmacology, Faculty of Dentistry, October University for Modern Sciences and Arts (MSA University), Giza, Egypt.

Förderung

  • Cairo University

Zitieren

APA

Ezeldine-Elmahalawy, N., Abdelkader, N. F., Zaki, H. F., Elbrairy, A. I., & Gad, S. S. (2025). Potential repurposing of lapatinib and pazopanib as neuroprotective agents in a rat model of Huntington’s disease. Inflammopharmacology. https://doi.org/10.1007/s10787-025-01933-5

Vancouver

Ezeldine-Elmahalawy N, Abdelkader NF, Zaki HF, Elbrairy AI, Gad SS. Potential repurposing of lapatinib and pazopanib as neuroprotective agents in a rat model of Huntington’s disease. Inflammopharmacology. 2025. doi:10.1007/s10787-025-01933-5

BibTeX
@article{EzeldineElmahalawy2025,
  author = {Ezeldine-Elmahalawy, Nada and Abdelkader, Noha F and Zaki, Hala F and Elbrairy, Amany I and Gad, Sameh S},
  title = {Potential repurposing of lapatinib and pazopanib as neuroprotective agents in a rat model of Huntington’s disease},
  journal = {Inflammopharmacology},
  year = {2025},
  doi = {10.1007/s10787-025-01933-5}
}
Kostenlos starten →